Thursday, May 21, 2020 9:47:53 PM
Some further musings
The Markman blog was comprehensive but erred in my view in some points:
BOTH statements are not true IMO. A situation of dangerous laissez-faire has arisen in the CAFC that threatens to ignore ad libitum the SCOTUS direction and prior precedent cases that support the Graham v. John Deere approach". "It requires considering all four Graham factors, including evidence of the fourth factor, secondary considerations, at once, before deciding the issue of obviousness.By so doing, it keeps the burden of proof on the challenger to prove obviousness by clear and convincing evidence, rather than transferring the burden of proof to the patentee to disprove obviousness using evidence of secondary considerations."
SCOTUS has mandated by prior judgements that the challenger's heavy burden of proof (by clear and convincing evidence) of obviousness not be transferred to the patentee--which has happened here due to lack of clear procedure and a judge Du who made horrific errors in her adoption of the "prima facie rebuttal approach". Analysis of all four Graham factors, including the fourth (secondary considerations) has become a nebulous and subjective exercise, subject to capriciously diverse interpretation across the spectrum of the CAFC bench.
Even assuming that a prima facie rebuttal approach is correct, it ASSUMES that the prima facie evaluation was done in good faith (open mind) and with proper attention to scientific facts and analysis and avoiding fatal errors of interpretation (not done bu Du).
So this is the crux of why the Du's conclusion of prima facie evidence of obviousness was flawed-- irrespective of what ensued in subsequent legal procedural error in terms of shifting burden of obviousness proof, and thereby weighting secondary factors (objective indicia) and using them to negate or reinforce an ab initio flawed prima facie obviousness assumption, as well as ignoring prior relevant case precedent and SCOTUS direction etc..
Two patient population arguments and their validity is highly relevant--part from having biological evidence for plausibility it directs the therapeutic approach and differentiates Vascepa as THE drug that lowers Triglycerides without raising LDL and lowering ApoB the key atherogenic particle that in essence carries the RISK inferred in elevated triglycerides--for a good summary read this article:
https://www.mayoclinicproceedings.org/article/S0025-6196(19)30678-0/pdf
This is why the Du misinterpretation of Kurabayashi data and infamous table is so disastrous, because it showed categorically the non-ApoB altering ability of EPA as administered in Kurayabashi's hands and in that population and using his EPA formulation.
Turning back to Mori et al and the much cited, much ado about nothing (scientific) article. It need placing in temporal and scientific context.
We are all by now familiar with Table 2 of the Mori article cited in the Du Judgement as supporting prima facie obviousness of EPA not raising LDL). This was a double-blind, placebo-controlled trial of parallel design, 59 overweight, nonsmoking, mildly hyperlipidemic men who were randomly assigned to receive 4 g purified EPA, DHA, or olive oil (placebo) daily while continuing their usual diets for 6 wk. We see from Table 2 which I attach that the 19 patients in each arm had an average TG level of 178 mg/dl NOT even close to 500 mg/dl. It is true that the EPA had no perceptible change on LDL c/w DHA that increased it, while both reduced TG's by 18-20%.
Purified eicosapentaenoic and docosahexaenoic acids have
differential effects on serum lipids and lipoproteins, LDL particle
size, glucose, and insulin in mildly hyperlipidemic men Mori et al Am J Clin Nutr 2000
However, let us now consider another MORI paper (Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension, Am J Clin Nutr 2002;76:1007–15) written in the year 2002 (2 years later). Here the same author Mori in conjunction with Woodman et al study 39 men 12 postmenopausal women with diabetes and hypertension and baseline Triglycerides of 119-154 mg/dl and what did they find? [b]EPA and DHA BOTH lowered triglycerides by 19% and 15% respectively BUT NEITHER CHANGED LDL CHOLESTEROL from baseline compared with olive oil control!!
So we have Mori studying "normal middle aged males" and shows differential LDL changes with TG lowering in ONE population then then he studies middle aged men (mostly) /postmenopausal women with diabetes and HTN and MILD hypertriglyceridemia (average TG at baseline =119-154 mg/dl)
For reference here is the population studied by Bays et al in the MARINE TRIAL:
It is clearly evident EVIDENT that even in the mildly hypertriglyceridemic population DIFFERENTIAL LDL effects were seen in normal males vs. Diabetic males/postmenopausal women ...what then can a POSA of circa 200-2002 discern...nothing at all...we needed larger better powered studies in clearly defined levels of hypertriglyceridemia
which is what the MARINE trial provided in 2011. Here we see EPA providing the profound TG lowering without raising LDL and IMPORTANTLY the apoB lowering that is the key to risk reduction and which is NOT shown by the Kurabayashi study of middle aged moderately hypertriglyceridemic (150-400 mg/dl) menopausal women. In this study, treatment with BOTH estriol estrogen and EPA (Epadel) showed c/w control estrogen, a statistically significant 8% reduction in LDL and a 16% reduction in Triglycerides WITHOUT a statistically significant reduction in apoB:
I conclude that NOTHING Mori published disclosed a jot about the LDL TG behavior of a population like MARINE with severely elevated TG's and the novel findings of powerful TG lowering WITH LDL neutral effects and significant ApoB reductions is what rightly pushed the USPTO examiner to recommend the granted MARINE patents to Amrn. In critical contrast Mori's data was confined to a TOTALLY DIFFERENT POPULATION WITH ENTIRELY DIFFERENT LEVELS OF TRIGLYCERIDES AND THE LIPID EFFECTS WERE SO DIVERGENT IN DIRECTION IN BOTH HIS STUDIES THAT BETWEEN 200-2011 NO POSA COULD HAVE CONCLUDED ANYTHING FROM THE DATA...
This is why the two population argument is both critical and holds water The second Woodman/Mori paper should be brought out by Singer at Appeal argument to show this critical point.No POSA would ever come to a conclusion of prima facie obviousness when confronted with this data.
Finally Mori concludes in a further paper in 1999 that he believes DHA is the promising compound for lowering BP and HR:
REFERENCES:
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:e7dd2fd6-0458-476f-a205-b716c28484c5
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:2a387396-bb58-4455-8fd3-56cc416299ed
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:8b337776-d2b2-4d7b-9fd8-124e02b57ae8
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:50c062d7-3929-466e-9d3a-f87df6e622e7
https://documentcloud.adobe.com/link/review?uri=urn:aaid:scds:US:2fc581eb-d884-4ff1-a486-a8ecac428c07
Recent AMRN News
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM